Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
about
Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled studyImpact of Data Imputation Methodology on Pain Assessment over 24 Hours in a Randomized, Placebo-Controlled Study of Gabapentin Enacarbil in Patients with Neuropathic Pain Associated with Postherpetic Neuralgia.Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidineRole of monocarboxylate transporters in drug delivery to the brain.Gabapentin enacarbil - clinical efficacy in restless legs syndromeGabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome.Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.Gabapentin enacarbil: in patients with restless legs syndrome.The use of gabapentin enacarbil in the treatment of restless legs syndrome.A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.Organic carbamates in drug design and medicinal chemistryRole of gabapentin enacarbil XR in restless legs syndromeTolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia.Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for cliniciansReview of the treatment of restless legs syndrome: focus on gabapentin enacarbil.A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?Targeting voltage-gated calcium channels for neuropathic pain management.Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery.Gabapentin enacarbil for the treatment of restless legs syndrome (RLS).Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.ADMET considerations for restless leg syndrome drug treatments.Gabapentin enacarbil: pharmacotherapy of restless legs syndromeADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome.A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy.Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.Gabapentin Enacarbil: A Review in Restless Legs Syndrome.Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use.The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials.Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.Pregabalin for the management of partial epilepsy.Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil.Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil.Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome.Low colonic absorption drugs: risks and opportunities in the development of oral extended release products.Modern prodrug design for targeted oral drug delivery.Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis.
P2860
Q24603670-8EBFA410-7FBE-434C-B0A7-C108EA11D3FDQ31040173-04579BF9-C1C1-4AE1-BFA3-F6221B19C6E7Q33795067-07DA2D76-E6FA-4960-B44A-8B42C36258EEQ33854710-4F0E565D-680B-417F-87C6-52CA747A5FE6Q33868110-4BFB799D-F5F5-49F3-ABCB-35625456EA2AQ34125935-17F399C5-B07E-4E1E-A8E1-951F43A3235FQ34228792-CDE34222-1930-497F-94D6-473CF4BC7222Q34313624-41644B30-37E4-4862-BB13-814E022BC4FEQ34409544-C4BF94A7-FBDE-4337-894B-C415C9039C83Q35042278-2F621961-CBF4-4E82-AB6F-F1475FAF25DEQ35365543-C1C2F29E-DCA7-4B72-B3DA-10228A388452Q35940214-543C72B7-93E9-4081-8C45-D1119F165491Q36084684-A5E061D1-4EF7-4D5E-A48D-836EB1486615Q36515513-BFFD1801-587C-427C-AA97-2CED260E67FFQ36748697-18D56A9B-795D-483B-9E0E-28912601D796Q37083130-622675FD-E7CC-49D7-B9E5-E7C5F7279851Q37577779-8A8E1A6C-5EBA-43BA-AC12-4F7267FDE594Q37605352-DDB52AB7-FE07-48D8-83E7-3E5777ED858EQ37824864-CFD01235-4E8F-4CA9-98F8-27533EE848E2Q37955269-76CAAE35-AC31-4B40-9771-C4606C99F9E9Q38019048-4EB0F3C8-A075-46DE-842C-8B784A9D637AQ38027180-3A3BACD9-1B50-432A-98AA-92BB2E2C1016Q38122149-86E32551-3482-493D-B316-D056214BC792Q38242390-3445688E-8ADA-4F74-9BDB-D8B7ECCFFC01Q38393782-F601A7B3-563A-482C-9C91-A00BC40C6C92Q38460680-A2FB1781-75CA-43E9-95B7-10F831859A32Q38586750-3FE15272-4B38-4917-8F86-7D61C4EC0A41Q38825763-265A098C-B3C4-456F-9F6D-C7B3CB14CC68Q38877302-B327FE87-0EEE-4FD0-BD45-2C19EE790012Q39838178-39713E0D-B4A1-47C5-B5F2-2087084116CDQ41621096-BD876216-130F-4162-82B6-AE71AE29E34FQ41848731-0CD607AC-5C15-4843-B55B-B1F39DADDC17Q43176295-2FF6F5B6-1795-4B05-B06B-5DB69F56D738Q44741365-FD8DEFC3-AE9B-41DE-901F-AAAB02C28B0EQ46153517-22300B1F-5E50-4996-AD08-08E0C7657940Q47980634-0F45AAD1-19B2-4DCD-9AAA-217F8DFC1991Q48301291-4AC246C3-2DDD-4510-A96C-29A0C1A66685Q49500092-E053A1C2-314E-4605-9ADD-76E94391A552Q51042522-526111DC-2608-455A-A210-FDD1187983C1Q53120499-E59E5C71-8209-469E-9BE5-415CCE8917B9
P2860
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@ast
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@en
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@nl
type
label
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@ast
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@en
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@nl
prefLabel
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@ast
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@en
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@nl
P2093
P2860
P356
P1476
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
@en
P2093
Daniel M Canafax
Kenneth C Cundy
Srikonda Sastry
Tristen L Moors
P2860
P304
P356
10.1177/0091270008322909
P577
2008-09-30T00:00:00Z